Investors & Media Overview


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

Learn More

Press Releases

10-May-22

Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported
27-Apr-22

Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary
18-Apr-22

Graybug to Present at the 2022 ASCRS Annual Meeting

BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming American Society of Cataract and
View All News